相似文献
1
Structure of the human mTOR complex I and its implications for rapamycin inhibition.
Mol Cell. 2010 Jun 11;38(5):768-74. doi: 10.1016/j.molcel.2010.05.017.
2
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
J Biol Chem. 2007 Jul 6;282(27):20036-44. doi: 10.1074/jbc.M702376200. Epub 2007 May 17.
3
Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity.
J Biol Chem. 2010 Dec 3;285(49):38362-73. doi: 10.1074/jbc.M110.141168. Epub 2010 Oct 11.
4
Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40.
Nature. 2017 Dec 21;552(7685):368-373. doi: 10.1038/nature25023. Epub 2017 Dec 13.
5
4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1.
Protein Cell. 2016 Dec;7(12):878-887. doi: 10.1007/s13238-016-0346-6. Epub 2016 Dec 1.
6
Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth.
Mol Cell Biol. 2009 Aug;29(15):4308-24. doi: 10.1128/MCB.01665-08. Epub 2009 Jun 1.
7
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
J Biol Chem. 2007 Jul 13;282(28):20329-39. doi: 10.1074/jbc.M702636200. Epub 2007 May 21.
8
Curcumin disrupts the Mammalian target of rapamycin-raptor complex.
Cancer Res. 2009 Feb 1;69(3):1000-8. doi: 10.1158/0008-5472.CAN-08-2367. Epub 2009 Jan 27.
9
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19.
10
Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.
Cell Cycle. 2009 Feb 15;8(4):567-72. doi: 10.4161/cc.8.4.7659. Epub 2009 Feb 18.
引用本文的文献
1
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.
Biomedicines. 2025 May 28;13(6):1319. doi: 10.3390/biomedicines13061319.
2
Quantitative Proteomics Unveils the Synergistic Effects of Combination Drugs on Cytoskeleton Composition and Autophagy-Mediated Cell Death in Neuroblastoma.
J Proteome Res. 2025 Jul 4;24(7):3578-3596. doi: 10.1021/acs.jproteome.5c00191. Epub 2025 Jun 17.
3
mTOR controls ependymal cell differentiation by targeting the alternative cell cycle and centrosomal proteins.
EMBO Rep. 2025 Apr 30. doi: 10.1038/s44319-025-00460-2.
4
TSC-mTORC1 Pathway in Postnatal V-SVZ Neurodevelopment.
Biomolecules. 2025 Apr 12;15(4):573. doi: 10.3390/biom15040573.
5
(-)-Epicatechin Rescues Memory Deficits by Activation of Autophagy in a Mouse Model of Tauopathies.
MedComm (2020). 2025 Mar 24;6(4):e70144. doi: 10.1002/mco2.70144. eCollection 2025 Apr.
6
JC virus small tumor antigen promotes S phase entry and cell cycle progression.
Tumour Virus Res. 2024 Dec;18:200298. doi: 10.1016/j.tvr.2024.200298. Epub 2024 Nov 23.
7
Phosphatidic acid directly activates mTOR and then regulates SREBP to promote ganoderic acid biosynthesis under heat stress in Ganoderma lingzhi.
Commun Biol. 2024 Nov 13;7(1):1503. doi: 10.1038/s42003-024-07225-y.
8
Mitophagy Unveiled: Exploring the Nexus of Mitochondrial Health and Neuroendocrinopathy.
J Mol Neurosci. 2024 Nov 8;74(4):107. doi: 10.1007/s12031-024-02280-w.
9
mTORC1 signaling and diabetic kidney disease.
Diabetol Int. 2024 Jun 20;15(4):707-718. doi: 10.1007/s13340-024-00738-1. eCollection 2024 Oct.
10
The "Road" to Malignant Transformation from Endometriosis to Endometriosis-Associated Ovarian Cancers (EAOCs): An mTOR-Centred Review.
Cancers (Basel). 2024 Jun 6;16(11):2160. doi: 10.3390/cancers16112160.
本文引用的文献
1
Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats.
Nature. 2010 Jan 7;463(7277):118-21. doi: 10.1038/nature08648. Epub 2009 Dec 20.
2
Molecular mechanisms of mTOR-mediated translational control.
Nat Rev Mol Cell Biol. 2009 May;10(5):307-18. doi: 10.1038/nrm2672. Epub 2009 Apr 2.
3
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
PLoS Biol. 2009 Feb 10;7(2):e38. doi: 10.1371/journal.pbio.1000038.
4
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.
J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.
5
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.
Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9. doi: 10.1073/pnas.0809136105. Epub 2008 Oct 27.
6
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.
Science. 2008 Jun 13;320(5882):1496-501. doi: 10.1126/science.1157535. Epub 2008 May 22.
7
Structure of TOR and its complex with KOG1.
Mol Cell. 2007 Aug 3;27(3):509-16. doi: 10.1016/j.molcel.2007.05.040.
8
Defining the role of mTOR in cancer.
Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008.
9
PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding.
J Biol Chem. 2007 Jul 6;282(27):20036-44. doi: 10.1074/jbc.M702376200. Epub 2007 May 17.
10
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.
Mol Cell. 2007 Mar 23;25(6):903-15. doi: 10.1016/j.molcel.2007.03.003.
Zotero 插件